ANI PHARMACEUTICALS INC
For the period ended Jun 30, 2026. Filed Aug 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 7, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Trading Arrangements
Our directors and executive officers may from time to time enter into plans or other arrangements for the purchase or sale of our common stock that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or may represent a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K).
On May 26, 2026, Nikhil Lalwani, President and Chief Executive Officer, adopted a Rule 10b5-1 trading plan. Mr. Lalwani's Rule 10b5-1 trading plan provides for a term commencing on August 25, 2026 and ending on December 31, 2026 for the sale of up to 26,990 shares of common stock of the Company.
On June 11, 2026, Renee Tannenbaum, member of the Board of Directors of the Company, adopted a Rule 10b5-1 trading plan. Ms. Tannenbaum's Rule 10b5-1 trading plan provides for a term commencing on September 10, 2026 and ending on December 31, 2026 for the sale of up to 6,655 shares of common stock of the Company.
On June 12, 2026, Jeanne Thoma, member of the Board of Directors of the Company, adopted a Rule 10b5-1 trading plan. Ms. Thoma's Rule 10b5-1 trading plan provides for a term commencing on September 11, 2026 and ending on December 31, 2026 for the sale of up to 5,395 shares of common stock of the Company.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.